Enclomiphene Citrate vs AndroGel: What to Do When One Fails

How Each Drug Works and Why That Determines How Each Fails

Enclomiphene and AndroGel sit at opposite ends of the testosterone-restoration spectrum. One coaxes your body to make more testosterone; the other simply replaces it. That mechanistic gap explains almost every clinical difference between them, including the distinct patterns of failure.

Enclomiphene Citrate: Amplifying Your Own Signal

Enclomiphene is the trans-isomer of clomiphene citrate. It competitively blocks estrogen receptors in the hypothalamus, which removes the negative-feedback brake on GnRH pulsing. The result is a rise in LH and FSH from the pituitary, which in turn drives Leydig cell production of testosterone inside the testes. Kim et al. (BJU Int, 2016) showed that enclomiphene at 12.5 mg and 25 mg daily raised mean total testosterone from approximately 230 ng/dL at baseline to 418 ng/dL and 489 ng/dL respectively at 12 weeks, while preserving or improving sperm concentration compared with transdermal testosterone.

Because enclomiphene depends on intact Leydig cell function, it fails when the testicular machinery itself is broken. Men with primary hypogonadism (Klinefelter syndrome, post-orchitis atrophy, or prior chemotherapy) simply cannot respond to a stronger LH signal. No amount of dose escalation will overcome dead Leydig cells.

AndroGel: Bypassing the Axis Entirely

AndroGel delivers pharmaceutical-grade testosterone through scrotal or non-scrotal skin. Absorption is highly variable. After a 5 g dose (delivering approximately 50 mg of testosterone), the FDA prescribing information reports a mean steady-state total T of approximately 400 to 550 ng/dL, but individual variability spans from below 300 to above 1,000 ng/dL in the same cohort.

Exogenous testosterone suppresses LH and FSH through negative feedback at the hypothalamus and pituitary. After 3 to 6 months of consistent use, endogenous production drops to near zero. This is not a side effect to manage around. It is the direct pharmacological consequence of replacing testosterone from outside.

AndroGel fails most often through poor transdermal absorption, not through the HPG axis. Thick skin, excessive body hair, high adiposity, and bathing within two hours of application each reduce delivery. Skin transfer to partners is a real clinical risk. The FDA issued a black-box warning specifically for virilization in women and children from secondary contact.

Defining "Failure" for Each Agent

Failure is not one thing. A man on enclomiphene who still feels symptomatic at week 12 may be a non-responder, or he may need a longer trial. A man on AndroGel with total T of 250 ng/dL may be a poor absorber, or he may be applying the gel incorrectly. Distinguishing these possibilities changes the next step.

What Enclomiphene Failure Looks Like

Clinical non-response to enclomiphene at 25 mg/day after 12 weeks of confirmed adherence is the operational definition most endocrinologists use. The key labs to check are:

• Total testosterone still below 400 ng/dL (or below the patient's symptomatic threshold)
• LH/FSH elevated above the upper limit of normal (this pattern suggests the testes, not the HPG axis, are the problem)
• LH/FSH low-normal or normal despite 25 mg/day (this suggests poor receptor sensitivity or a defect upstream of the hypothalamus)

If LH and FSH are high and T remains low, the patient has primary hypogonadism masked by secondary presentation, or the Leydig cell reserve is simply exhausted. Enclomiphene cannot fix this. Switch to exogenous testosterone.

If LH and FSH are unexpectedly low on enclomiphene, consider whether the diagnosis was correct. Structural pituitary disease (prolactinoma, Sheehan-equivalent) may be at play and requires MRI before any switch.

What AndroGel Failure Looks Like

Poor response to AndroGel almost always traces to one of four causes:

1. Application error (wrong site, insufficient drying time, showering too early)
2. Genuinely poor transdermal absorption
3. Rapid hepatic clearance of absorbed testosterone (less common with gel than injections, but possible)
4. Target lab misinterpretation (sampling too soon or too late after application)

The Testosterone Trials (T-Trials, N=788 men aged 65 and older) used AndroGel 1% titrated to achieve serum testosterone of 500 to 750 ng/dL and achieved that target in roughly 77% of participants after dose optimization, meaning about 23% required adjustments or remained subtherapeutic. Snyder et al. (NEJM, 2016) described the protocol in detail, demonstrating that standardized application technique materially reduces the absorption variance that leads clinicians to prematurely call failure.

The Decision Framework: What to Do When One Fails

The following structured approach is used by the HealthRX clinical team when a patient presents with a confirmed inadequate response to either agent at the correct dose after an adequate trial duration.

Step 1: Confirm True Failure Before Switching

For enclomiphene: re-check adherence and timing. Enclomiphene is best taken in the morning with food to reduce nausea and improve consistency. Confirm the patient has been on 25 mg/day for at least 12 consecutive weeks, not 12 weeks with gaps. Retest total T, free T, LH, FSH, and estradiol in a single morning blood draw (before 10 a.m., per Endocrine Society guideline).

For AndroGel: confirm the blood draw happened 2 to 6 hours after gel application (the window of peak absorption). Confirm the application site has been rotated and that the patient has not been showering within 2 hours of application. If labs still show total T below 350 ng/dL on 81 mg/day (the maximum labeled dose of AndroGel 1.62%), true gel failure is confirmed.

Step 2: Identify the Mechanism of Failure

| Scenario | Most Likely Cause | Recommended Next Step | |---|---|---| | Enclomiphene + high LH/FSH + low T | Primary hypogonadism | Switch to exogenous T (AndroGel or injectable) | | Enclomiphene + low LH/FSH + low T | Pituitary pathology | MRI pituitary; consider endocrinology referral | | Enclomiphene + normal LH/FSH + borderline T | Partial Leydig response | Dose escalation or switch | | AndroGel + low T + confirmed technique | Poor absorber | Switch to IM testosterone cypionate or enanthate | | AndroGel + high T + persistent symptoms | Free T or SHBG issue | Check SHBG; calculate free T | | AndroGel + high T + polycythemia | Over-replacement | Dose reduction; consider switch |

Step 3: Manage the Transition Safely

Switching from enclomiphene to AndroGel requires no washout. Enclomiphene's half-life is approximately 10 hours for the enclomiphene isomer; within 48 to 72 hours it has largely cleared. You may start AndroGel the morning after the last enclomiphene dose. Expect LH and FSH to fall within 4 to 6 weeks as exogenous testosterone suppresses the HPG axis.

Switching from AndroGel to enclomiphene is the harder transition. The HPG axis has been suppressed. Recovery time varies from 6 weeks to 6 months depending on duration of prior testosterone use, age, and baseline Leydig cell reserve. A reasonable protocol is:

1. Stop AndroGel.
2. Retest total T, LH, and FSH at 6 weeks.
3. If LH and FSH have not recovered above the lower limit of normal, the axis is still suppressed. Wait another 4 weeks.
4. If LH and FSH have recovered and T is still below 300 ng/dL, the patient is now showing his true baseline. This is the ideal time to start enclomiphene at 12.5 mg/day and titrate.
5. If LH and FSH have recovered and T has also recovered to an acceptable range (above 400 ng/dL), the patient may not need any treatment. Consider a watchful waiting period of 8 to 12 weeks with symptom monitoring before prescribing again.

Fertility Considerations: A Deciding Factor Many Men Miss

Fertility status should be the first question asked before initiating any testosterone-related therapy, because it sharply narrows the choice.

AndroGel suppresses spermatogenesis. The American Urological Association guideline on male infertility states directly that exogenous testosterone should not be used in men who desire fertility, because LH suppression removes the intratesticular testosterone surge required for sperm maturation. Men who start AndroGel and then decide they want children face a recovery timeline of 6 to 24 months, with no guarantee of full return to baseline sperm counts.

Enclomiphene was specifically studied in this context. Kim et al. (2016) found that enclomiphene 25 mg/day for 12 weeks increased median sperm concentration from 33 million/mL at baseline to 46 million/mL at 12 weeks, while the transdermal testosterone arm showed a decline from 33 million/mL to 11 million/mL over the same period. That is a meaningful divergence in reproductive outcome from the same starting point.

For any man under 40 who has not completed his family, enclomiphene is the first-line choice unless there is a confirmed contraindication, such as primary hypogonadism or a known SERM hypersensitivity.

Side Effect Profiles and What Changes After a Switch

Enclomiphene Side Effects

• Visual disturbances (flashing lights, blurred vision). These are class effects of SERMs and occur in roughly 1 to 2% of users. If they appear, stop the drug immediately and evaluate with ophthalmology. They are largely reversible.
• Estrogen-related symptoms in some men (mood changes, mild gynecomastia) because enclomiphene raises aromatizable testosterone.
• Elevated estradiol. Check estradiol at 6 and 12 weeks. If estradiol rises above 42.6 pg/mL (the upper limit of the reference range used in most assays), consider a low-dose aromatase inhibitor or dose reduction.

AndroGel Side Effects

• Erythrocytosis (hematocrit above 54%). The Endocrine Society clinical practice guideline (2018) recommends stopping or dose-reducing testosterone therapy if hematocrit exceeds 54%, due to increased thrombosis risk. Check CBC at baseline, 3 months, and annually thereafter.
• Acne and oily skin, particularly in younger men.
• Testicular atrophy from LH suppression. This is cosmetic for most men but can be addressed by adding hCG 500 IU twice weekly if desired.
• Skin transfer to household contacts. The FDA black-box warning on this is not a theoretical concern. Documented cases of clitoromegaly in female partners and early puberty in children have been reported from casual skin contact with application sites.

What Typically Improves After Switching

When a man who was a poor enclomiphene responder switches to AndroGel, the most consistent improvements are in libido and energy within 4 to 8 weeks of reaching a therapeutic serum level. Sexual function improvements in the T-Trials were statistically significant at 6 months in men who maintained T above 500 ng/dL. Snyder et al. (NEJM, 2016) reported that the sexual activity subscore improved by a mean of 1.4 points on the PDAS scale (P<0.001) versus placebo.

When a man switches from AndroGel to enclomiphene after a careful washout, the benefit is restoration of the HPG axis with preservation of testicular volume and fertility potential. Subjective energy improvements may take longer (12 to 16 weeks) because enclomiphene-driven T rises more gradually than a direct gel application.

Monitoring After a Switch: Lab Schedule and Target Ranges

After Switching to AndroGel

| Timepoint | Labs to Order | |---|---| | Baseline (before starting) | Total T, free T, LH, FSH, estradiol, CBC, PSA, lipid panel | | 6 weeks | Total T (2 to 6 hrs post-application), hematocrit | | 3 months | Total T, free T, estradiol, CBC, PSA | | 6 months | Full baseline panel repeat | | Annually | Full panel, DEXA if osteoporosis risk |

Target total T: 400 to 700 ng/dL for most symptomatic men, per Endocrine Society (2018). Do not routinely target above 700 ng/dL without documented clinical need, as the erythrocytosis risk rises sharply above 800 ng/dL.

After Switching to Enclomiphene

| Timepoint | Labs to Order | |---|---| | Baseline | Total T, LH, FSH, estradiol, semen analysis (if fertility relevant) | | 6 weeks | Total T, LH, FSH, estradiol | | 12 weeks | Full panel; decision point for dose escalation or switch | | 6 months | Full panel; ongoing monitoring |

Target total T on enclomiphene: 400 to 600 ng/dL is the typical achievable range in men with adequate Leydig reserve. Men who plateau below 400 ng/dL at 25 mg/day after 12 weeks have not responded and should be reclassified.

When Neither Drug Works: Next Steps

A subset of men will not respond adequately to either agent. This is not rare. Defined as persistent total T below 350 ng/dL or persistent symptoms despite documented serum levels in range, it occurs in roughly 10 to 15% of patients across both modalities in clinical practice.

Options to consider in sequence:

1. Injectable testosterone cypionate or enanthate (100 to 200 mg IM every 7 to 14 days). These bypass all absorption variability and achieve more predictable peaks and troughs. Many men who absorb gel poorly respond well to intramuscular delivery.

2. Testosterone pellets (Testopel). Subcutaneous implants lasting 3 to 6 months. Absorption is consistent and eliminates the daily compliance requirement.

3. Evaluate for and treat contributing factors. Sleep apnea, obesity (BMI above 30), opioid use, and high-dose corticosteroid therapy each suppress testosterone independently. CDC data shows that 34% of men with OSA have co-existing hypogonadism, and treating the apnea alone raises T by a mean of 50 to 100 ng/dL in some cohorts.

4. Endocrinology or urology referral. If LH and FSH remain unexpectedly suppressed despite stopping all testosterone therapy for 8 weeks, structural pituitary imaging (MRI with gadolinium) is indicated to rule out a mass lesion.